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ABSTRACT
Purpose: Several case reports have described familial aggregation of transitional cell carcinoma 
of the urinary tract but to our knowledge only 1 epidemiological study specifically addressed the 
issue of familial bladder cancer. We evaluated the extent of familial aggregation of transitional 
cell carcinoma among the population of Iceland.
M aterials and Methods: The first to third degree relatives of 190 patients with bladder, ureter 
or renal pelvis transitional cell carcinoma diagnosed between 1983 and 1992 in Iceland were 
identified through the Icelandic Cancer Family Resource. The records of these 12,328 relatives 
were subsequently linked to the 1965 to 1994 cancer registry. The observed occurrence of 
transitional cell carcinoma of the urinary tract was compared to the expected occurrence based 
on age, gender and calendar specific incidence rates, Observed-to-expected ratios and 95% 
confidence intervals were calculated.
Results: In 41 of the 190 pedigrees at least 1 relative had transitional cell carcinoma of the 
urinary tract. Of the probands 38 had only 1 and 3 had 2 affected relatives. The prevalence of 
family history of transitional cell carcinoma was 3% in first degree and 10% in first or second 
degree relatives. The risk of transitional cell carcinoma among all relatives was slightly elevated 
(observed~to-expected ratio 1.24, 95% confidence interval 0.90 to 1.67). The observed-to- 
expected ratio was greater among second and third degree relatives than  among first degree 
relatives.
Conclusions: The risk of transitional cell carcinoma among relatives of patients is somewhat 
increased. However, the greater risk for more distant relatives argues against the existence of a 
hereditary subtype of bladder transitional cell carcinoma, at least in the founder population of 
Iceland.
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The last decade has shown an increasing interest in inher­
ited forms of common malignancies, which has led to the 
identification of tumor suppressor genes in breast and ovar­
ian cancer, melanoma and renal cell cancer, and to the dis­
covery of mismatch repair genes in colon cancer. Transitional 
cell carcinoma of the urinary tract is the fourth most frequent 
type of cancer among white men.1 Numerous case reports 
have described families with transitional cell carcinoma,2 
some of which are convincing for m end el i an inheritance.3 
Recently, a gerinline chromosomal abnormality was found in 
a bladder cancer kindred.'1 Furthermore, it has been shown 
that the risk of upper urinary tract but not bladder transi­
tional cell carcinoma is increased more than 10-fold in fam­
ilies with hereditary nonpolyposis colon cancer,5 Neverthe­
less, to our knowledge only 1 epidemiological study to date 
has specifically addressed the issue of familial bladder can­
cer.« In that study, the risk of bladder cancer for first degree 
relatives of patients was increased by a factor of 2.
Iceland is a small northern Atlantic island with a popula­
tion of approximately 250,000. The Icelandic Cancer Society 
has kept a population based cancer registry since 1955 and has 
identified relatives of select sets of cancer patients since 
1972, This unique infrastructure prompted us to evaluate the
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extent of familial clustering of transitional cell carcinoma 
among this fairly isolated population.
METHODS
The Icelandic Cancer Society has kept a nationwide cancer 
registry since 1955. The primary source of the registry is the 
department of pathology of the University of Iceland, which 
covers the entire country regarding histopathological diag­
noses of human material.7 For this study patients were se­
lected from the registry if they met various criteria, including 
newly diagnosed transitional cell carcinoma (ICD-0 morphol­
ogy codes 8120 to 8130) of the bladder, ureter or renal pelvis 
(ICD-7 site codes 180 and 181) between 1983 and 1992, age at 
diagnosis 70 years or younger, patient born in Iceland and 
tumor extending into or beyond the lamina propria or carci­
noma in situ (stage pTa papillary carcinomas are not regis­
tered in Iceland).
A family tree was constructed for all probands. The neces­
sary information was obtained from existing records of the 
Genetic al Committee of the University of Iceland or from 
reported genealogies. A standard approach was used for con­
struction of the pedigree. The grandparents of the probands 
were identified and all descendents of the grandparents were 
identified insofar as they were related to the proband in the 
first, second or third degree. Through this routine pedigtees 
were constructed with all first, second and third degree rel­
atives of the proband except for the great grandparents and
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the siblings of the grandparents. Family data of select sets of 
cancer patients have been collected in Iceland since 1972 and 
are now referred to as the Icelandic Cancer Family Re­
source.8
Cases of transitional cell carcinoma among relatives, in­
cluding persons related by marriage, were identified by cross- 
linking the unique personal identification codes with the 
1965 to 1994 Icelandic Cancer Registry (until 1965 the reg­
istry did not distinguish renal cell cancer from renal pelvic 
transitional cell carcinoma). To compare the observed with 
the expected number of cases we first defined the foliowup 
of the relatives as the number of person-years from 1965 or 
age 15 years, whichever came later, until diagnosis of trans­
itional cell carcinoma, death, the end of 1994 or age 90 years, 
whichever came first. Subsequently, the observed person- 
years were stratified by gender, 5-year age category and 
5-year calendar period. The strata specific total numbers of 
person-years were multiplied with the Icelandic gender, age 
and calendar year specific transitional cell carcinoma inci­
dence rates. Finally, observed-to-expected ratios of transi­
tional cell carcinoma with corresponding 95% confidence in­
tervals were calculated using Byar’s approximation of the 
exact Pois son test.9 Since information on tumor stage and 
grade is not readily available from the Icelandic Cancer Reg­
istry it was not possible to stratify the analyses based on 
these characteristics. However, the case reports do not pro­
vide any indication that familial transitional cell carcinoma 
is correlated with a more or less virulent form of transitional 
cell carcinoma.2
Statistical analysis software was used for computations. 
For the calculation of strata specific person-years we used 
the method described by Pearce and Checkoway.10 Based on 
the results from the folio wup study in New York,6 we esti­
mated that we would reach a power of 99% to detect a 2-fold 
increased risk among relatives of 200 cases (a 0.05, 1-sided). 
For a risk increased by 50% we estimated power to be 73%.
RESULTS
Of 145 male and 45 female probands who met the inclusion 
criteria, 11 (6%) were diagnosed with upper urinary tract 
transitional cell carcinoma only. After construction of the 
pedigrees it appeared that 5 probands were related in 
the third degree to another proband. The pedigrees of these 5 
probands were excluded from the analyses only when the risk 
of transitional cell carcinoma for third degree relatives was 
evaluated. None of the pedigrees met the Amsterdam criteria 
for the diagnosis of hereditary nonpolyposis colon cancer.11 
There were 12,328 relatives (an average of 65 per proband) 
and 3,730 persons related by marriage identified through the 
Icelandic Cancer Family Resource. In 38 pedigrees 1 relative 
was diagnosed with transitional cell carcinoma between 1965 
and 1994. In 3 pedigrees 2 relatives had transitional cell 
carcinoma, including a brother-brother and a brother-sister 
combination. The prevalence of family history of transitional 
cell carcinoma was 3% in first degree, 10% in first or second 
degree and 22% in first, second or third degree relatives.
Of all probands 10 (5%) were diagnosed when they were 
younger than 40 years. Only 1 of them (age 22 years) had a 
relative with transitional cell carcinoma (second degree, age 
72 years). Mean age of probands with and without transition­
al cell carcinoma in the family was not different (59.4 and
58.5 years, respectively). Likewise, the probands with a first 
degree relative were not younger than those with a more 
distant relative with transitional cell carcinoma. Compared 
to other Icelanders the first degree relatives of transitional 
cell carcinoma patients did not appear to have an increased 
risk of cancer (see table). An increased risk, although not 
statistically significant, was found for more distant relatives. 
Overall, 44 relatives were diagnosed with transitional cell 
carcinoma when 35 were expected (observed-to-expected ra-
Observed versus expected cases o f  transitional cell cancer in  










First 1,635 6 6.22 0.96 0.35-2.10
Second 4,648 13 9.45 1.38 0.73-2.35
Third* 6,045 25 19.70 1.27 0,82-1.87
First-Third 12,328 44 35.37 1.24 0.90-1.67
Married in-laws 3,730 10 11.94 0.84 0.40-1.54
* Five pedigrees were excluded from this analysis because the probands 
were related to another proband in the third degree.
tio 1.24, 95% confidence interval 0.90 to 1.67). This increased 
risk seemed to be restricted to male relatives; 36 cases of 
transitional cell carcinoma were observed versus 26 expected 
(observed-to-expected ratio 1.36, 95% confidence interval
0.95 to 1.88). Among female relatives 8 cases of transitional 
cell carcinoma were observed versus 9 expected (observed-to- 
expected ratio 0.90, 95% confidence interval 0.39 to 1.78). 
Comparable results were obtained when the risk of bladder 
cancer instead of the risk of transitional cell carcinoma was 
evaluated (data not shown).
DISCUSSION
The study of inherited forms of cancer may result in spe­
cific knowledge of the pathogenesis of inherited and spoi’adic 
variants of the disease. Therefore, much attention has been 
given to hereditary subtypes of the common malignancies, 
such as breast cancer, colon cancer, melanoma and renal cell 
carcinoma. In all of these malignancies specific genes have 
already been identified. In addition, the existence of inher­
ited forms of prostate cancer and lung cancer has been sug­
gested by segregation analyses.12’13
The evidence for the existence of familial transitional cell 
carcinoma from epidemiological studies conducted to date is 
far from consistent,2 probably due at least partly to the fact 
that almost all studies evaluated familial clustering of blad­
der cancer as 1 of many hypotheses. Most of these studies 
used an ill-defined definition of family history. The largest 
study of bladder cancer is a population based study of 2,982 
patients and 5,782 controls conducted in 1978 (the United 
States National Bladder Cancer Study).14 Of bladder cancer 
patients 6% versus 4% of the controls had a first degree 
relative with cancer of the urinary tract. The odds ratio 
adjusted for race, sex, smoking and age was calculated to be
1.5 (95% confidence interval 1.2 to 1.8). This risk appeared to 
be somewhat greater in persons younger than 45 years (odds 
ratio 2.7, 95% confidence interval 0.8 to 2.9) and in female 
patients (odds ratio 1.8, 95% confidence interval 1.1 to 2.7). 
Since the evaluation of familial cancer was not a major ob­
jective of this study, the authors were not able to distinguish 
bladder cancer from kidney cancer nor were they able to 
verify the reports on familial cancer occurrence.14 Piper et al 
performed a case-control study in young women, the group 
with a greater than average odds ratio for family history in 
the aforementioned United States National Bladder Cancer 
Study.15 A total of 162 women with bladder cancer 20 to 49 
years old was matched to population controls and questioned 
regarding bladder or kidney cancer (renal cell and transition­
al cell carcinoma) history in first degree relatives. Of the 
patients and controls 4 (2.5%) and 1 (0.6%), respectively, 
reported a positive family history but only 1 patient reported 
bladder cancer in the father, and 1 reported that a sister had 
had papillary cancer of the kidney and ureter. The remaining
2 patients and 1 control reported kidney cancer in the father. 
The major disadvantage of case-control studies that are not 
initiated to address the issue of familial aggregation is that 
the exposure (transitional cell carcinoma in the family) is 
measured by a simple question to the patients and controls.
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In that situation no adjustment can be made for the total 
number of relatives, age, sex, smoking status and age at 
diagnosis of the relatives. Kramer et al collected demo­
graphic data and cigarette smoking status on all first degree 
relatives of 319 male bladder cancer patients diagnosed in 
New York and 319 neighborhood controls.6 The 2 cohorts of 
relatives were then associated with the New York State 
tumor registry to obtain valid data on cancer occurrence. A 
total of 14 cases of bladder cancer was found among 1,619 
relatives of patients and 7 were found among the 1,773 rel­
atives of controls (observed-to-expected ratio 1.9, 90% confi­
dence interval 1.1 to 2.7). Goldgar et al estimated familial 
risk ratios from the Utah population data base by identifying 
all cases of cancer in first degree relatives of cancer patients. 
The observed values were compared to those expected based 
on cohort specific internal rates calculated from 400,000 rel­
atives of all individuals in the Utah population data base 
known to have died in Utah. A total of 48 bladder cancers was 
observed in the 1,452 first degree relatives of bladder cancer 
patients when only 31 were expected (relative risk 1.5, 95% 
confidence interval 1.0 to 2.2). Among relatives of probands 
with early age bladder cancer (younger than 60 years) the 
relative risk was 5.1 (95% confidence interval 1.0 to 12.5).
We used a comparable approach to that of the New York 
and Utah studies. Pedigree information and data on cancer 
occurrence in the pedigrees were collected from existing 
records. The family members were not asked about the struc­
ture of the family or cancer in the family, which leaves recall 
bias impossible. It appeared that the prevalence of family 
history of transitional cell carcinoma was greater (10% in 
first or second degree relatives) than reported in the litera­
ture (2 to 8%“), which indicates some degree of mis classifica­
tion of family history in the epidemiological studies con­
ducted until now. On the other hand, familial clustering is 
not as strong as previously reported. The risk of transitional 
cell carcinoma among relatives of patients with the disease 
was increased by approximately 25% although this increase 
was not statistically significant. Since we were not able to 
adjust for the effects of environmental factors, such as smok­
ing behavior and occupation, the increased risk we observed 
for third degree relatives would favor a genetic cause of this 
familial clustering. After all, familial aggregation of environ­
mental factors is not likely to exist beyond the first or second 
degree. On the other hand, the findings that the risk of 
transitional cell carcinoma is not increased in first degree 
relatives as well as that patients with a relative with trans­
itional cell carcinoma are not younger than those without 
such a relative strongly argue against an inherited subtype of 
transitional cell carcinoma. These findings are in contradic­
tion with all of the case reports and particularly with the 
studies of Kramer15 and Goldgar10 et al. The explanation for 
this discrepancy is not clear. Possibly our study was ham­
pered by small numbers. Although our study included the 
entire country of Iceland during 3 decades only 6 cases of 
transitional cell carcinoma were expected among first degree 
relatives. Whereas the power of the study was sufficient to 
detect clustering in all relatives it was not sufficient to detect 
clustering in first degree relatives only.
Another possible explanation is that familial transitional
cell carcinoma may be underrepresented in the founder pop­
ulation of Iceland. The original settlers of Iceland in the 
latter part of the ninth and the beginning of the tenth cen­
turies were mainly from Norway with some minor admixture 
from southern Sweden, Denmark and the British isles. After 
Iceland was fully settled little immigration occurred from 
outside. If these settlers did not carry certain susceptibility 
genes the existence of hereditary subtypes of diseases may 
remain undetected. Thus, the advantage of the unique infra­
structure of Iceland regarding data collection for genetic ep­
idemiological studies may be overruled by the characteristics 
of its population. Therefore, further research in different 
populations will be necessary.
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